Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection
0
Pipeline Programs
4
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Colorado TherapeuticsCO - Louisville
1 programInfusion of 200% maintenance fluids as balanced crystalloid IV solutionN/A
Allergy TherapeuticsUK - West Sussex
1 programInfusion of 200% maintenance fluids as balanced crystalloid IV solutionN/A1 trial
Active Trials
Utah MedicalIreland - Dublin
1 programInfusion of 200% maintenance fluids as balanced crystalloid IV solutionN/A
Oregon TherapeuticsFrance - Paris
1 programInfusion of 200% maintenance fluids as balanced crystalloid IV solutionN/A
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
Allergy TherapeuticsInfusion of 200% maintenance fluids as balanced crystalloid IV solution
Clinical Trials (1)
Total enrollment: 1,040 patients across 1 trials
NCT05219110Allergy TherapeuticsInfusion of 200% maintenance fluids as balanced crystalloid IV solution
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
Start: Sep 2022Est. completion: Aug 20271,040 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 1,040 patients
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.